600849.SH
Shanghai Pharmaceuticals Holding Co., Ltd.
Healthcare · Medical - Distribution · CN
Sep 10, 2026, 10:48 UTC
Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.
Source:Sep 7, 2026, 13:50 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.
Source:Aug 27, 2026, 11:08 UTC
Shanghai Pharmaceuticals declared an interim dividend of RMB 0.10 per share for the six months ended June 2026, down from RMB 0.12 per share in the prior year.
Source:Aug 27, 2026, 09:19 UTC
Shanghai Pharmaceuticals reported a net profit of 3.50 billion yuan for the first half of 2026.
Aug 24, 2026, 11:57 UTC
Shanghai Pharmaceuticals' subsidiary Shanghai Hefeng Pharmaceutical received NMPA approval for promethazine hydrochloride injection to pass generic consistency evaluation.
Source:Aug 24, 2026, 11:57 UTC
Shanghai Pharmaceuticals announced that its wholly-owned subsidiary Shanghai Pharma Holding will publicly list for transfer its 51% stake in subsidiary Shanghai Shangyao Xinte Dong'an Pharmacy Co., Ltd. via a property rights exchange, with a proposed minimum price of 179 million yuan.
Source:Aug 18, 2026, 00:17 UTC
Hangzhou Huqingyutang Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, started construction of a production workshop with an annual capacity of 2.2 billion capsules on August 15, 2026.
Source:Aug 3, 2026, 07:33 UTC
Shanghai Pharmaceuticals' subsidiary SPH Sine received a drug registration certificate from the National Medical Products Administration for omeprazole and sodium bicarbonate dry suspension (I), approving its production.
Source:Jul 30, 2026, 07:51 UTC
Shanghai Pharmaceuticals' subsidiary Shangyao Zhonghua received product licenses from Health Canada for three Longhu products: classic and strong versions of cooling balm and Longhu rollerball essential balm.
Source:Jul 30, 2026, 07:51 UTC
Shanghai Pharmaceuticals' subsidiary Changzhou Pharmaceutical Factory received a drug registration certificate from the National Medical Products Administration approving the production of Rosuvastatin/Ezetimibe Tablets (I).
Jul 24, 2026, 09:58 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. signed a limited partnership agreement to invest 300 million yuan as a limited partner in the Shanghai Shangshi Biomedical Industry Private Equity Fund Partnership.
Jul 20, 2026, 07:52 UTC
Shanghai Pharmaceuticals' subsidiary Shangyao Zhongyaosuo received a drug clinical trial approval notice from the National Medical Products Administration for Qingrun Yangmu Granules to treat dry eye.
Source:Jul 17, 2026, 12:09 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. plans to list and transfer its 41% stake in subsidiary Shangyao Yiyi Pharmaceutical (Shanghai) Co., Ltd. via a public auction at a property rights exchange, with a base price of 330 million yuan.
Source: